RT Journal Article
SR Electronic
T1 A novel art of continuous non-invasive blood pressure measurement
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2019.12.10.19013938
DO 10.1101/2019.12.10.19013938
A1 Jürgen Fortin
A1 Dorothea Rogge
A1 Christian Fellner
A1 Doris Flotzinger
A1 Julian Grond
A1 Katja Lerche
A1 Bernd Saugel
YR 2020
UL http://medrxiv.org/content/early/2020/01/07/2019.12.10.19013938.abstract
AB Wearable sensors to continuously measure blood pressure (BP) and derived cardiovascular variables have the potential to revolutionize patient monitoring. Current wearable methods analyzing time components (e.g., pulse transit time) still lack clinical accuracy, whereas existing technologies for direct BP measurement are too bulky. Here we present a new art of continuous non-invasive arterial blood pressure monitoring (CNAP2GO). It directly measures BP by using a new “volume control technique” and could be used for small wearable sensors integrated in a finger ring. As a software prototype, CNAP2GO showed excellent BP measurement performance in comparison with invasive BP in 46 patients having surgery. The resulting pulsatile BP signal carries information to derive cardiac output and other hemodynamic variables. We show that CNAP2GO can be miniaturized for wearable approaches. CNAP2GO potentially constitutes the breakthrough for wearable sensors for blood pressure and flow monitoring in both ambulatory and in-hospital clinical settings.Competing Interest StatementCNSystems Medizintechnik GmbH (Graz, Austria) develops, manufactures and markets the non-invasive CNAP-Technology. JF is CEO and founder of CNSystems, receives salary and has equity interests. CF, DF, JG and KL are employees of CNSystems. JF, CF, JG and KL are inventors and named on one or more patents regarding continuous non-invasive technologies. BS has received institutional restricted research grants, honoraria for giving lectures, and refunds of travel expenses from CNSystems. DR has no conflicts to declare.Clinical TrialThe study was purely oberservational and hence not registered.Funding StatementThe study was financed by CNSystems Medizintechnik GmbH, Austria. A major part of the investment came from a crowdfunding initiative (https://www.lionrocket.com/cnsystems) and the authors thank all crowd investors.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable